{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"81.7","value":"14.1"},{"groupId":"OG001","spread":"64.1","value":"13.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"115"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"title":"7-day post-infusion AUC (AUC(d0-7)) - Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"79.1","value":"19.1"},{"groupId":"OG001","spread":"65.0","value":"18.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"66"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 1, Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.0","value":"11.3"},{"groupId":"OG001","spread":"65.0","value":"10.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"104"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 2, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"64.7","value":"14.9"},{"groupId":"OG001","spread":"60.2","value":"15.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"88"},{"groupId":"OG001","value":"57"}],"units":"Participants"}],"title":"AUC(d0-7) - Cycle 2, Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"74.7","value":"25.9"},{"groupId":"OG001","spread":"76.4","value":"22.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"title":"14-day post-infusion AUC (AUC(d0-14)) - Cycle 1, Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.2","value":"19.1"},{"groupId":"OG001","spread":"65.0","value":"21.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"title":"AUC(d0-14) - Cycle 2, Day 15"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"AUC was derived from the PK blood samples collected.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants in Cohort 1 had received prior treatment with platinum-containing chemotherapy. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG000","title":"Enfortumab Vedotin - Cohort 1"},{"description":"Participants in Cohort 2 had received no platinum-containing chemotherapy were ineligible for treatment with cisplatin at the time of enrollment. Enfortumab vedotin, at a dose of 1.25 mg/kg, was administered to participants as an IV infusion over approximately 30 minutes on Days 1, 8, and 15 of each 28-day cycle.","id":"OG001","title":"Enfortumab Vedotin - Cohort 2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set: all participants who received enfortumab vedotin and from whom at least one blood sample was collected and assayed for enfortumab vedotin, MMAE or Tab concentration. Corresponding records of the time of dosing and sample collection must also be available for all enfortumab vedotin. Here, 'Overall Number of Participants Analyzed'=number of participants evaluable for this outcome measure. Here, 'Number Analyzed'= participants evaluable at specified timepoints.","reportingStatus":"POSTED","timeFrame":"AUC0-7 was assessed (in cycles 1 and 2) based on concentration data from Day 1 to Day 8 (pre dose) and AUC0-14 was assessed based on data from D15 (pre dose) to D29 (pre-dose)","title":"PK Parameter for Free MMAE: AUC (Plasma)","type":"SECONDARY","unitOfMeasure":"Day*nanogram per milliliter"}